SBH
RYTM icon

Segall Bryant & Hamill’s Rhythm Pharmaceuticals RYTM Stock Holding History

Segall Bryant & Hamill’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Buy
+121,866
New +$11M 0.16% 209

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Segall Bryant & Hamill's RYTM Position: Q2 2026 in Review

Segall Bryant & Hamill opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 121,866 shares worth $13.5M. The stake represents 0.16% of the portfolio and ranks #209 among its holdings.

303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Segall Bryant & Hamill held 121,866 shares of Rhythm Pharmaceuticals worth $13.5M as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Segall Bryant & Hamill position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.16% of Segall Bryant & Hamill's portfolio in Q2 2026, its #209 holding.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.